PML risk in Natalizumab-treated patients
Anti–JCV antibody status
Prior immunosuppressant use?
Duration of Natalizumab exposure
References
- TYSABRI Indication and important safety information. https://www.tysabrihcp.com/en_us/home/safety/risk-pml-jcv.html